Lars Fruergaard Jørgensen How a love story launched the company behind Ozempic, Wegovy Novo Nordisk, the pharma giant behind Ozempic and Wegovy, has surprising love story origins.

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

Novo Nordisk appoints Maziar Mike Doustdar as the new CEO to tackle falling sales and shares amid stiff competition in the ...

Bagsværd, Denmark, 16 May 2025– Novo Nordisk today announced changes to its executive leadership and Board of Directors. As per mutual agreement with the Novo Nordisk Board, Lars Fruergaard ...

Maziar Mike Doustdar, who was named as Novo Nordisk’s new CEO last week, spoke on a second quarter earnings call of ...

Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 ...

Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.

(Bloomberg) -- When Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen dialed into a Teams video call with Chairman Helge Lund, he was expecting an ordinary catchup.

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...

Novo Nordisk CEO Lars Fruergaard Jørgensen Steps Down, Stock Drops In Pre-market May 16, 2025 — 07:57 am EDT Written by RTTNews.com for RTTNews -> ...

Novo Nordisk A/S (NVO) Q4 2019 Earnings Conference Call February 5, 2020 7:00 AM ET Company Participants Lars Fruergaard Jørgensen - CEO Mads Krogsgaard Thomsen - Chief Science Officer Karsten ...